This is a five-part study that will take place in the Bronx, New York (NY), and Washington, District of Columbia (DC). The different components of the study will focus on increasing the number of people being tested for HIV, evaluating ways to link HIV-infected people to HIV care sites, evaluating methods to reinforce antiretroviral therapy (ART) adherence, and evaluating a counseling program that focuses on HIV prevention. (Details for only three components of this study are included in ClinicalTrials.gov (Linkage-to-Care, Viral Suppression and Prevention for Positives) because they are the only ones that were randomized and had prescriptive interventions.)
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Expanded HIV Testing Component: Number and results of HIV tests per month in publicly funded testing sites (local health department data)
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Number, transmission category, and testing source of newly identified cases in HIV surveillance data
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Initial CD4 cell count of newly identified HIV cases in surveillance data
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Number of newly identified HIV cases concomitantly diagnosed with AIDS in surveillance data
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Proportion of persons in the community tested for HIV in the last year (local population-based behavioral surveys)
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Proportion and number of total ED visits and admissions to hospital where patients receive HIV testing
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Number of HIV tests in EDs where HIV infection is newly identified
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Number of HIV tests in hospital admissions where patients receive HIV testing
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Proportion of hospital admissions who have newly identified HIV infection
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Number of tested patients identified with previously diagnosed HIV who are not in care
Timeframe: Measured at Month 36
Expanded HIV Testing Component: Cost of support for additional staff and HIV tests
Timeframe: Measured at Month 36
Linkage-to-Care Component: Number of individuals eligible for incentives and number of individuals receiving incentives (upon linkage to HIV care) at participating sites
Timeframe: Measured at Month 24
Linkage-to-Care Component: Cost of the program, including staffing, infrastructure, and incentives
Timeframe: Measured at Month 24
Linkage-to-Care Component: Proportion of HIV-infected people at each site with newly detected HIV infection or who were previously diagnosed but were out of care, and who are presently linked to care
Timeframe: Measured at Month 24
Linkage-to-Care Component: Mean time interval at each site from HIV diagnosis (Western Blot confirmation) to first CD4 cell count or viral load for those with newly detected HIV infection and those who were previously diagnosed but were out of care
Timeframe: Measured at Month 24
Linkage-to-Care Component: Proportion of HIV-infected people at a testing site with at least two CD4 cell count and viral load measurements in the prior year
Timeframe: Measured at Month 24
Viral Suppression Component: Number of individuals eligible for incentives and receiving incentives at a select subset of sites for select time points
Timeframe: Measured at Month 24
Viral Suppression Component: Cost of program, including staffing, infrastructure, and incentives
Timeframe: Measured at Month 24
Viral Suppression Component: Probability of an HIV-infected patient in care at a site having a suppressed viral load (less than 400 copies/mL) in the 12-month calendar assessment period beginning 12 months after initiation of the assessment period
Timeframe: Measured at Month 24
Viral Suppression Component: Number of identified HIV-infected patients in care who have sustained viral suppression
Timeframe: Measured at Month 24
Prevention for Positives Component: Proportion of participants reporting any unprotected vaginal or anal sex in the previous 3 months
Timeframe: Measured at Month 12 and 18